Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation

Weiyang Lou1,2,3†, Jing Chen4,5†, Bisha Ding1,2,3†, Danni Chen1,2,3, Huilin Zheng1,2,3, Donghai Jiang1,2,3, Liang Xu1,2,3, Chang Bao1,2,3, Guoqiang Cao1,2,3 and Weimin Fan1,2,3,6*

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most lethal cancer, mainly attributing to its high tendency to metastasis. Vascular invasion provides a direct path for solid tumor metastasis. Mounting evidence has demonstrated that microRNAs (miRNAs) are related to human cancer onset and progression including invasion and metastasis.

Methods: In search of invasion-metastasis-associated miRNAs in HCC, microarray dataset GSE67140 was downloaded from the Gene Expression Omnibus database. Differentially expressed miRNAs (DE-miRNAs) were obtained by R software package and the potential target genes were predicted by miRTarBase. The database for annotation, visualization and integrated discovery (DAVID) was introduced to perform functional annotation and pathway enrichment analysis for these potential targets of DE-miRNAs. Protein–protein interaction (PPI) network was established by STRING database and visualized by Cytoscape software. The effects of the miR-494-3p and miR-126-3p on migration and invasion of HCC cell lines were evaluated by conducting wound healing assay and transwell assay.

Results: A total of 138 DE-miRNAs were screened out, including 57 upregulated miRNAs and 81 downregulated miRNAs in human HCC tumors with vascular invasion compared with human HCC tumors without vascular invasion. 762 target genes of the top three upregulated and downregulated miRNAs were predicted, and they were involved in HCC-related pathways, such as pathway in cancer, focal adhesion and MAPK signaling pathway. In the PPI network, the top 10 hub nodes with higher degrees were identified as hub genes, such as TP53 and MYC. Through constructing the miRNA-hub gene network, we found that most of hub genes could be potentially modulated by miR-494-3p and miR-126-3p. Of note, miR-494-3p and miR-126-3p was markedly upregulated and downregulated in HCC cell lines and tissues, respectively. In addition, overexpression of miR-494-3p could significantly promote HCC migration and invasion whereas overexpression of miR-126-3p exerted an opposite effect.

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Hepatocellular carcinoma (HCC) is a high aggressive malignancy which mortality is nearly tantamount to its incidence [1]. It ranks the third most common causes of cancer-related death worldwide [2]. A variety of factors lead to the fearful situation, among which metastasis is the main one. Metastasis is a complicated process involving several sequential steps, including local invasion, intravasation, transport and survival in the circulatory system, extravasation, and settlement and proliferation in a new site [3]. As liver is an organ rich in blood vessel, vascular invasion is extremely frequent in clinical patients with HCC. Vascular invasion has a close connection with metastasis because it provides a direct path for cancer metastasis, and is a common precursor to occurrence of metastasis. Increasing studies have shown that cancer invasion and metastasis are closely associated with multiple biological processes, like degradation of extracellular matrix (ECM) [4], epithelial–mesenchymal transition (EMT) [5], immune evasion [6], homing of circulating cancer cells and cancer stem cells (CSCs) [7]. However, the detailed molecular mechanisms that manipulate invasion and metastasis of HCC are largely unknown and need to be further elucidated. Furthermore, most of effective targeted therapeutic drugs for HCC are unavailable.

MicroRNAs (miRNAs) are a group of small endogenous single-stranded non-coding RNAs, approximately 21–25 nucleotides in length [8]. MiRNAs can negatively modulate gene expression via binding to the 3′-untranslated region of messenger RNA (mRNA), thereby leading to direct degradation of mRNA or suppression of protein translation. Through this approach, miRNAs are involved in regulation of many biological processes such as proliferation, apoptosis, cell cycle and differentiation and DNA repair [9]. Over the past decades, mounting studies have demonstrated that miRNA is frequently abnormally expressed in various types of cancer including HCC [10], and the dysregulation of miRNA plays a paramount role in tumorigenesis, invasion and metastasis [11]. However, research exploring invasion-metastasis-associated miRNAs in HCC based on large-scale human tissues are rarely seen.

With the rapid development of gene chip and RNA sequencing technologies, Gene Expression Omnibus (GEO) gradually plays an important role in bioinformatic analysis [12]. It can provide us novel clues for discovering reliable and functional miRNAs. In this study, differentially expressed miRNAs (DE-miRNAs) in HCC samples with or without vascular invasion were screened out using miRNA expression profile of GSE67140. The potential target genes of the top three most upregulated and downregulated miRNAs were predicted by miRTarBase, and their potential functions were analyzed by gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Moreover, a protein–protein interaction (PPI) network of these predicted target genes and miRNA-gene regulatory network were constructed by Cytoscape software. Next, the expression levels of the top 3 most upregulated and downregulated miRNAs in HCC cell lines were determined. Finally, we evaluated miR-494-3p and miR-126-3p on invasion and migration of HCC cell lines. The aim of present study is to explore and identify invasion-metastasis-associated miRNAs and their potential molecular mechanisms based on comprehensive bioinformatic analysis and related experimental validation.

Methods

MiRNA microarray

In the discovery step, we only included datasets that compared the miRNA expression in invasive/metastatic HCC cell or tissue with non-invasive/metastatic HCC cell or tissue. Besides, only datasets containing more than twenty samples were included. The titles and abstracts of these datasets were screened, and the full information of the datasets of interest were further evaluated. Finally, only GSE67140 dataset was selected to further study. The dataset GSE67140 based on the platform of GPL8786 (Affymetrix Multispecies miRNA-a Array) contained 91 human HCC tumor samples without vascular invasion and 81 samples with vascular invasion was downloaded from the National Center for Biotechnology Information (NCBI) GEO database (https://www.ncbi.nlm.nih.gov/geo).

Screening for DE-miRNAs

Data were normalized using the normalizeBetweenArray function from R package ‘LIMMA’ from the bioconductor project [13]. Data before and after normalization were shown in Fig. 1a, b, respectively. The miRNA differential expression analysis was conducted using the limma software package in the Bioconductor package (http://www.bioconductor.org/). The related codes were put into R,
and the DE-miRNAs in HCC tumor samples with vascular invasion compared to HCC tumor samples without vascular invasion were analyzed through the limma package. \( P \)-value < 0.05 and |fold change (FC)| > 2 were set as the thresholds for identifying DE-miRNAs.

**Prediction of target genes**
The potential target genes of the top three most upregulated and downregulated miRNAs were predicted by miRTarBase (http://miRTarBase.mbc.nctu.edu.tw/php/index.php), which is an experimentally validated microRNA-target interactions database [14].

**GO and pathway analysis**
The database for annotation, visualization and integrated discovery (DAVID 6.8, http://david-d.ncifcrf.gov/) was introduced to perform functional annotation and pathway enrichment analysis for the predicted targets of the selected 6 DE-miRNAs, including GO and KEGG pathway analysis [15, 16]. \( P \)-value < 0.05 was considered as statistically significant.

**PPI network and miRNA-gene network construction**
PPI network and miRNA-gene network were successively constructed. The target genes were first mapped to the STRING database (http://string-db.org) to assess functional associations among these target genes [17]. Only the interactions with a combined score > 0.4 were considered as significant. Next, to obtained the hub genes, the degree of connectivity in the PPI network was analyzed by Cytoscape software (version 3.6.0), after which miRNA-hub gene network was established.

**Cell lines and clinical samples**
The human HCC cell lines HepG2, Bel-7402, HCCLM3 and SMMC7721 and normal cell line HL7702 were kindly provided by the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China). HepG2, Bel-7402, HCCLM3 and HL7702 were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco,12430047) supplemented with 10% fetal bovine serum (FBS; Biological Industries, 04-0101-1, Cromwell, CT, USA) and SMMC7721 was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, 31800105, Life Technologies, Carlsbad) containing 10% FBS under a humidified atmosphere of 5% CO\(_2\) at 37 °C. HCC tumor tissues and matched noncancerous tissues were also obtained from the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China).

**Cell transfection**
The miRNA mimics and negative control (purchased from RiboBio, Guangzhou, China) were transfected into HCC cell lines using Lipofectamine™ 3000 according to the manufacturer's instruction.

**RNA extraction and quantitative-PCR (qPCR)**
RNAiso plus Reagent (TaKaRa, Kusatsu, Japan) was introduced to extract total RNA from HCC cell lines and clinical samples. Subsequently, miRNAs reverse transcription primers and q-PCR primers were purchased...
from Ribobio Co. Ltd (Guangzhou, China). Q-PCR was performed in triplicates by SYBR Premix Ex Taq (TaKaRa, RR420A). The U6 small nuclear RNA was used as the internal control. The 2^{-ΔΔCT} method was utilized to determine fold change in the RNA level of each sample compared with the reference sample.

**The Cancer Genome Atlas database**
The expression levels of miR-494-3p and miR-126-3p in HCC tissue from the Cancer Genome Atlas (TCGA) database (https://genome-cancer.ucsc.edu/) were determined. Firstly, the miRNA-sequencing data in patients of liver cancer was downloaded from the database. Then, miR-494-3p and miR-126-3p expression values were extracted, after which unpaired Student’s t-test was employed to conduct statistical analysis between normal group and tumor group. A P-value < 0.05 was considered as significant.

**Wound healing assays**
Cells were plated in six-well plates with 1 × 10⁵ cells per well. After transfection (50 nM), the cells were grown to 100% confluence in six-well plates. Then, a micropipette tip was applied to make a cross wound. Photographs were taken by a microscopy immediately or 24 h after wounding.

**Transwell assay**
The cell invasion assay was performed using 24-well transwell chambers (Corning, USA). Firstly, the inserts were coated with Matrigel (BD Bioscience, USA) on the upper surface. After transfection (50 nM), 1 × 10⁵ cells were suspended in 0.2 ml serum-free medium and added to the inserts. 0.6 ml medium with 20% FBS was added to the lower compartment as a chemoattractant. After incubation at 37 °C for 48 h, the cells on the upper surface of the membrane were carefully removed using a cotton bud and cells on the lower surface were successively fixed with 100% methanol and stained with 0.1% crystal violet. Five visual fields of 200× magnification of each insert were randomly selected and counted under a light microscope (Olympus, Japan).

**Analysis of target gene expression using UALCAN database**
UALCAN, a portal for facilitating tumor subgroup gene expression and survival analyses, provides easy access to publicly available cancer transcriptome data including TCGA [18]. The database was utilized to analyze the expression levels of potential targets of miR-494-3p and miR-126-3p between normal tissue and tumor tissue. In brief, gene symbols were firstly pasted in the text area, and liver hepatocellular carcinoma dataset was chosen. Then, the expression information of each target gene could be acquired by linking to gene expression analysis result. Statistical analysis of comparison between normal group and tumor group was performed and log-rank P-value was observed in the database.

**Survival data from Kaplan–Meier plotter**
The prognostic values of miR-494-3p and miR-126-3p in HCC were analyzed using Kaplan–Meier plotter (KM plotter) database [19]. In brief, the two miRNAs were entered into the database, after which Kaplan–Meier survival plots were generated and hazard ratio (HR), 95% confidence intervals (CI), log rank P-value were displayed on the webpage. P-value of < 0.05 was regarded as statistically significant.

**Statistical analysis**
The results were shown as mean ± SD. Differences between two groups were estimated using unpaired Student’s t-test. A two-tailed value of P < 0.05 was considered as statistically significant.

**Results**

**Identification of DE-miRNAs and their target genes**
To identify DE-miRNAs of miRNA array GSE67140 downloaded from GEO, we conducted a differential expression analysis using limma software package. Based on this analysis, a total of 138 miRNAs were found to be significantly differentially expressed in HCC tumor samples with vascular invasion more than two-fold when compared to HCC tumor samples without vascular invasion, including 57 upregulated and 81 downregulated miRNAs. For better visualization, the top ten most upregulated miRNAs and top ten most downregulated miRNAs were presented in Tables 1 and 2, respectively. According to fold change (FC), miR-494-3p, miR-1207-5p and miR-1268a were the top three most upregulated miRNAs; and miR-126-3p, miR-199a-3p and miR-199b-3p were the top three most downregulated miRNAs. 485 potential target genes were predicted for the three upregulated miRNAs and 277 genes for the three downregulated miRNAs by using miRTarBase. A volcano plot of these DE-miRNAs was provided in Fig. 2.

**GO functional enrichment analysis**
Three categories of GO functional annotation analysis were performed on these potential target genes mentioned above, including biological process (BP), cellular component (CC) and molecular function (MF). As shown in Fig. 3a1–a3, the enriched GO functions for target genes of the three upregulated miRNAs included the regulation of transcription, transcription, regulation of programmed cell death, regulation of cell death and regulation of apoptosis in the BP category; intracellular
Table 1 Top ten upregulated differentially expressed miRNAs between HCC tumor with vascular invasion and without vascular invasion

| miRNA      | Log2FC | AveExpr | t     | P value | adj.P.val | B     |
|------------|--------|---------|-------|---------|-----------|-------|
| hsa-miR-199a-3p | 3.49273 | 7.052915 | 13.3399 | 2.38E-28 | 2.88E-26 | 53.79083 |
| hsa-miR-199b-3p | 3.46525 | 7.057111 | 13.0789 | 1.33E-25 | 1.13E-25 | 52.08226 |
| hsa-miR-126-3p  | 3.36828 | 9.212248 | 13.2869 | 3.38E-28 | 3.58E-26 | 53.44345 |
| hsa-miR-195-5p  | 3.19533 | 7.128742 | 15.3637 | 4.02E-34 | 3.41E-31 | 66.96628 |
| hsa-miR-30a-5p  | 3.14494 | 7.071084 | 13.2253 | 5.07E-28 | 4.78E-26 | 53.04028 |
| hsa-miR-143-3p  | 3.07323 | 9.16678  | 11.141  | 4.62E-22 | 2.17E-20 | 39.44342 |
| hsa-miR-100-5p  | 2.90109 | 8.128079 | 10.7776 | 4.92E-21 | 1.90E-19 | 37.10007 |
| hsa-miR-19b-3p  | 2.878469 | 7.51099 | 10.8113 | 3.96E-21 | 1.60E-19 | 37.31624 |
| hsa-miR-21-5p   | 2.85469 | 5.884845 | 14.4948 | 1.18E-31 | 3.34E-29 | 61.33273 |
| hsa-miR-146b-5p | 2.81179 | 6.432729 | 10.1073 | 3.72E-19 | 1.17E-17 | 32.81846 |

Table 2 Top ten downregulated differentially expressed miRNAs between HCC tumor with vascular invasion and without vascular invasion

| miRNA      | Log2FC | AveExpr | t     | P value | adj.P.val | B     |
|------------|--------|---------|-------|---------|-----------|-------|
| hsa-miR-199a-3p | −3.49273 | 7.052915 | 13.3399 | 2.38E-28 | 2.88E-26 | 53.79083 |
| hsa-miR-199b-3p | −3.46525 | 7.057111 | 13.0789 | 1.33E-25 | 1.13E-25 | 52.08226 |
| hsa-miR-126-3p  | −3.36828 | 9.212248 | 13.2869 | 3.38E-28 | 3.58E-26 | 53.44345 |
| hsa-miR-195-5p  | −3.19533 | 7.128742 | 15.3637 | 4.02E-34 | 3.41E-31 | 66.96628 |
| hsa-miR-30a-5p  | −3.14494 | 7.071084 | 13.2253 | 5.07E-28 | 4.78E-26 | 53.04028 |
| hsa-miR-143-3p  | −3.07323 | 9.16678  | 11.141  | 4.62E-22 | 2.17E-20 | 39.44342 |
| hsa-miR-100-5p  | −2.90109 | 8.128079 | 10.7776 | 4.92E-21 | 1.90E-19 | 37.10007 |
| hsa-miR-19b-3p  | −2.878469 | 7.51099 | 10.8113 | 3.96E-21 | 1.60E-19 | 37.31624 |
| hsa-miR-21-5p   | −2.85469 | 5.884845 | 14.4948 | 1.18E-31 | 3.34E-29 | 61.33273 |
| hsa-miR-146b-5p | −2.81179 | 6.432729 | 10.1073 | 3.72E-19 | 1.17E-17 | 32.81846 |

non-membrane-bounded organelle, non-membrane-bounded organelle, membrane-enclosed lumen, organelle lumen and intracellular organelle lumen in the CC category; and DNA binding, transcription regulator activity, transcription factor binding, RNA binding and sequence-specific DNA binding in the MF category. The enriched GO functions for target genes of the three downregulated miRNAs were presented in Fig. 3b1–b3, involving the regulation of transcription, regulation of RNA metabolic process, positive regulation of cellular biosynthetic process, positive regulation of macromolecule metabolic process and phosphorylation in the BP category; membrane-enclosed lumen, organelle lumen, intracellular organelle lumen, nuclear lumen and cytosol in the CC category; and transcription regulator activity, adenyl ribonucleotide binding, ATP binding, purine nucleoside binding and nucleoside binding in the MF category.

KEGG pathway enrichment analysis

To further analyze the enriched pathways of these target genes, we subsequently conducted KEGG pathway enrichment analysis. For upregulated miRNAs (Fig. 4a), the enriched KEGG pathways contained pathways in cancer, focal adhesion, glioma, neurotrophin signaling pathway and insulin signaling pathway. And the enriched KEGG pathways for downregulated miRNAs (Fig. 4b) included pathways in cancer, focal adhesion, MAPK signaling pathway, neurotrophin signaling pathway and chemokine signaling pathway. Interestingly, both target genes of upregulated miRNAs and targets of downregulated miRNAs were enriched in the process, focal adhesion. Accumulating evidence has demonstrated that dysregulation of focal adhesion plays a central role in cell invasion and migration [20]. Therefore, 17 genes (PRKCA, HRS, TLN1, MAP2K1, PPP1CC, PTEN, AKT1, VEGFB, MAPK1, IGF1R, CCND1, ARHGAP5, BCL2, RAC1, PPP1R12A, RAP1A, RAP1B) of upregulated miRNAs and 21 genes (PIK3CG, CAV2, FLT1, ROCK1, MET, IGF1, ITGA3, HGF, KDR, AKT1, MAPK1, CRKL, PAK4, BCL2, VEGFA, MAPK9, MAPK8, CRK, PIK3R1, AKT2, PIK3R2) of downregulated miRNAs which are involved in focal adhesion may interact with the selected 6 miRNAs, thereby modulating invasion and metastasis in HCC.
miR-126-3p might be two potential regulators of invasion and metastasis in HCC.

Next, we further evaluated the expression of potential targets of miR-494-3p and miR-126-3p in HCC using the UALCAN database as shown in Fig. 6. The analytic results suggested that the expression of five (CYCS, MAPK1, PTEN, AKTI, BCL2) in six targets of miR-494 was significantly upregulated in HCC tissue than normal tissue whereas MYC gene was markedly downregulated. It is widely acknowledged that there is an inverse relationship between miRNA expression and target gene expression. Thus, among these detected genes, the significantly downregulated MYC may be the most potential target for the upregulated miR-494-3p. Similarly, these significantly upregulated genes including AKTI, BCL2, MAPK8, VEGFA and KRAS may be the most potential targets for the downregulated miR-126-3p in theory.

Aberrant expression and prognostic roles of miR-494-3p and miR-126-3p in HCC

Based on our previous findings, we intended to further determine the expression and prognostic roles of miR-494-3p and miR-126-3p in HCC. Firstly, we evaluated the expression of miR-494-3p and miR-126-3p in four HCC cell lines (HepG2, Bel7402, SMMC7721 and HCCLM3) compared with that in normal liver cell line (HL7702). The results presented in Fig. 7a, d demonstrated that miR-494-3p expression was markedly upregulated and miR-126-3p expression were significantly downregulated in all four HCC cell lines. Of note, expression of miR-494-3p and miR-126-3p in HCCLM3 is the most upregulated and downregulated compared with other three cell lines. HCCLM3 is a high metastatic HCC cell [21], further suggesting miR-494-3p and miR-126-3p may regulate HCC metastasis. The expression of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC cell lines was also detected (Additional file 1: Figure S1). However, the expression of them was only significantly dysregulated in one or two HCC cell lines as shown in Additional file 1: Figure S1. To some extent, the result hinted that the functional roles of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC may be not as good as miR-494-3p and miR-126-3p. Besides, miR-494-3p and miR-126-3p expression in 70 pairs of clinical tumor and normal samples also demonstrated a higher expression of miR-494-3p and a lower expression of miR-126-3p in HCC tissues than normal tissues (Fig. 7c, f), further hinting promoting and suppressive roles of miR-494-3p and miR-126-3p in HCC, respectively. Moreover, for miR-126-3p, similar results were obtained by downloading and analyzing HCC data from the Cancer Genome Atlas (TCGA) (Fig. 7e). However, for miR-494-3p, there was no significant difference between
tumor tissue and normal tissue (Fig. 7b). To summarize, miR-494-3p was upregulated and miR-126-3p was downregulated in HCC, suggesting that they may play a major role in the onset and progression of HCC, especially in HCC invasion and metastasis.

KM plotter database was utilized to assess the prognostic values of the two potential miRNAs, miR-494-3p and miR-126-3p in HCC. As shown in Fig. 7g, high expression of miR-494-3p was significantly correlated with worse OS, further implying that miR-494-3p is an oncogene in HCC. Figure 7h indicated a favorable prognostic role of miR-126-3p in HCC. In short, all these findings suggest that miR-494-3p and miR-126-3p are aberrantly expressed in HCC and can serve as two prognostic
Fig. 4  KEGG pathway enrichment analysis of target genes of six selected DE-miRNAs. a For upregulated miRNAs, b for downregulated miRNAs. Only the enriched pathways with \( P \)-value < 0.001 were presented. The red lines represent count and the blue lines represent \(-\log_{10}(P\text{-value})\).
biomarkers. Therefore, the two miRNAs, miR-494-3p and miR-126-3p were selected for further experimental excavation and research.

**In vitro effects of miR-494-3p and miR-126-3p on HCC migration and invasion**

In the first place, miR-494-3p and miR-126-3p expression in HepG2 and HCCLM3 after transfected with miRNA mimics at final concentrations of 20, 50 and 100 nM were detected using qPCR (Additional file 2 : Figure S2). To determine the roles of miR-494-3p and miR-126-3p in HCC migration, we first performed a wound healing assay. As shown in Fig. 8, wound healing assay suggested that miR-494-3p overexpression markedly enhanced HepG2 and HCCLM3 migration whereas overexpression of miR-126-3p could significantly attenuate cell migration, when compared with negative control cells. Next, a transwell invasion assay was employed to measure the effects of miR-494-3p and miR-126-3p on HCC invasion. The results presented in Fig. 9 demonstrated that upregulation of miR-494-3p and miR-126-3p could evidently boost and suppress cell invasion, respectively. All these data confirmed that miR-494-3p and miR-126-3p were two key regulators of HCC invasion and metastasis. Targeting miR-494-3p and miR-126-3p may represent novel approaches in treating HCC patients with vascular invasion or/and distant metastasis, thus improving the prognosis of patients with HCC.

**Discussion**

HCC, a high heterogeneous malignancy, which prognosis is extremely dismal, mainly attributing to its tendency to invade and metastasize. To date, effective therapeutic strategies against invasive or/and metastatic HCC is still rare. Therefore, it is imperative need to seek and develop

---

**Table 3 Hub genes identified in the PPI interaction**

| Upregulated miRNAs | Gene symbol | Degree | Downregulated miRNAs | Gene symbol | Degree |
|--------------------|-------------|--------|-----------------------|-------------|--------|
| TP53               | 80          |        | MYC                   | 42          |        |
| AKT1               | 72          |        | AKT1                  | 39          |        |
| MAPK1              | 61          |        | VEGFA                 | 38          |        |
| MYC                | 51          |        | MAPK8                 | 35          |        |
| BCL2               | 46          |        | PIK3CG                | 35          |        |
| HRAS               | 46          |        | BCL2                  | 28          |        |
| PTEN               | 46          |        | FGF2                  | 22          |        |
| CALM3              | 45          |        | KRAS                  | 22          |        |
| CDKN1A             | 44          |        | PIK3R1                | 21          |        |
| CYCS               | 40          |        | SIRT1                 | 21          |        |

PPI protein–protein interaction

---

**Fig. 5** The regulatory network between dysregulated miRNAs and hub genes. a For upregulated miRNAs; b for downregulated miRNAs
a promising therapeutic target to improve the survival of patients with advanced HCC.

MiRNAs are a group of small, endogenous non-coding RNAs which possess a variety of biological functions, including modulating cell metabolism and cell survival [22, 23]. Recent studies showed that miRNA is involved in HCC invasion and metastasis by post-transcriptionally regulating gene expression. For example, the team of Liao CG found that miR-10b promotes migration and invasion of HCC via direct repression of RhoC, uPAR and MMPs [24]. In addition, Yang et al. [25] suggested that miR-34a is involved in Treg cell recruitment and promotes venous metastases of HBV-positive hepatocellular carcinoma. However, systemic analysis of miRNA’s roles in HCC invasion and metastasis remain absent.

In this study, we discovered some invasion-metastasis-associated miRNAs by performing a differential expression analysis on a microRNA array downloaded from GEO datasets. According to node degree, top ten hub genes of three upregulated miRNAs and three downregulated miRNAs were screened out. By constructing miRNA-gene network, we found that most of hub genes

---

**Fig. 6** The mRNA expression of predicted targets of miR-494-3p and miR-126-3p from the UALCAN database. a) CYCS expression; b) MAPK1 expression; c) PTEN expression; d) AKT1 expression; e) BCL2 expression; f) MYC expression; g) MAPK8 expression; h) VEGFA expression; i) KRAS expression; j) PIK3CG expression; k) PIK3R1 expression; l) SIRT1 expression
could be potentially modulated by miR-494-3p and miR-126-3p. Recent studies have suggested that miR-494-3p is linked to the occurrence and development of various types of cancer, including nasopharyngeal carcinoma, oral cancer, non-small cell lung cancer, gastric cancer and osteosarcoma [26–30]. MiR-126-3p is also reported to suppress cancer proliferation, migration and increase chemosensitivity [31–34]. To the best of our knowledge, however, the roles of miR-494-3p and miR-126-3p in HCC, especially in invasion and metastasis of HCC, have not been studied. It is extremely meaningful to authenticate the functions of miR-494-3p and miR-126-3p in HCC and elucidate the mechanisms how they regulate HCC invasion and metastasis.

Q-PCR data revealed that miR-494-3p and miR-126-3p were significantly upregulated and downregulated in...
both cell lines and clinical samples. Subsequently, in vitro wound healing assay and transwell invasion assay suggested that overexpression of miR-494-3p and miR-126-3p could markedly promote and suppress HCC migration and invasion, respectively. In addition, GO annotation and KEGG pathway analysis on the predicted target genes of the top three most upregulated and downregulated miRNAs were conducted using DAVID, and the results demonstrated that some of these target genes were enriched in focal adhesion. It has been well documented that focal adhesion is closely associated with cell migration and invasion [20]. Therefore, targeting these genes may be one of the mechanisms that miR-494-3p and miR-126-3p exert their effects on invasion and metastasis in HCC.

In a word, we confirmed that miR-494-3p and miR-126-3p are aberrantly expressed in both HCC cell lines and clinical samples and are two crucial regulators of HCC invasion and metastasis and can serve as prognostic biomarkers in HCC. However, there are still some limitations in this study: (1) only target genes of the top three most upregulated and downregulated miRNAs are selected for further enrichment analysis; (2) among the six selected miRNAs, only miR-494-3p and miR-126-3p are selected for experimental verification which may lead to omit some functional miRNAs; (3) a lack of research on detailed molecular mechanisms that miR-494-3p and miR-126-3p regulate invasion and metastasis of HCC is another limitation; (4) related animal studies are deficient in this study.

**Conclusion**

In conclusion, we have successfully identified two invasion-metastasis-associated miRNAs (miR-494-3p and miR-126-3p) based on bioinformatic analysis and experimental validation. The present study suggested that miR-494-3p and miR-126-3p play key roles in invasion and metastasis of HCC.
metastasis of HCC and can be exploited as two promising targets in treating HCC patients with vascular invasion and metastasis.

Additional files

Additional file 1: Figure S1. The expression levels of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC cell lines. (A) The expression of miR-1207-5p in HCC cell lines was compared with that in normal liver cell line (HL7702); (B) the expression of miR-1268a in HCC cell lines was compared with that in HL7702; (C) the expression of miR-199a-3p in HCC cell lines was compared with that in HL7702; (D) the expression of miR-199b-3p in HCC cell lines was compared with that in HL7702. Ns represents no significance; *P < 0.05; **P < 0.01. Error bars represent s.d. for n = 3.

Additional file 2: Figure S2. After transfected with mimic at indicated concentration (20 nM, 50 nM and 100 nM), miR-494-3p and miR-126-3p expression levels were significantly increased in both HepG2 and HCCLM3 cell lines. Ns represents no significance; *P < 0.05. Error bars represent s.d. for n = 3. MiR-494-3p and miR-126-3p expression levels were detected using q-PCR at 48 h post-transfection.

Abbreviations
HCC: hepatocellular carcinoma; ECM: extracellular matrix; EMT: epithelial–mesenchymal transition; CSC: cancer stem cell; miRNA: microRNA; mRNA: messenger RNA; GEO: Gene Expression Omnibus; PPI: protein–protein interaction; NCBI: National Center for Biotechnology Information; DAVID: the database for annotation, visualization and integrated discovery; GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; FBS: fetal bovine serum; BP: biological process; CC: cellular component; MF: molecular function.

Authors’ contributions
WYL and WMF designed the study. WYL wrote the manuscript. JC and BSD revised and polished the manuscript. WYL, JC and BSD performed the experiments and statistical analysis of the data. DNC conducted some experiments. HLZ, DHJ, LX, CB and GQC collected clinical samples. All authors read and approved the final manuscript.

Author details
1 Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China. 2 Key Laboratory of Organ Transplantation, Hangzhou 310003, Zhejiang, China. 3 Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310000, China. 4 Department of Oncology, The First Hospital of Jiaxing, Jiaxing 314000, Zhejiang, China. 5 First Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang, China. 6 Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Acknowledgements

This work was supported by National Natural Science Foundation of China grants (81372462, 81572987) and the Department of Science and Technology of Zhejiang Province (2014C03012). Thanks for the anonymous reviewers for their valuable comments and suggestions that helped improve the quality of our manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Please contact author for data requests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Institutional Ethics Review Board of the First Affiliated Hospital, College of medicine, Zhejiang University, Zhejiang, China.

Funding

The National Natural Science Foundation of China (Nos. 81372462 and 81572987), the Department of Science and Technology of Zhejiang Province (Nos. 81372462 and 81572987), the Department of Science and Technology of Zhejiang Province (No. 2017M621953).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Wu H, Tao J, Li X, Zhang T, Zhao L, Wang Y, Zhang L, Xiong J, Zeng Z, Zhan N, et al. MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice. Hepatology. 2017;66:1952–67.
2. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–51.
3. Jafri MA, Al-Qahtani MH, Shay JW. Role of miRNAs in human cancer metastasis: implications for therapeutic intervention. Semin Cancer Biol. 2017;44:117–31.
4. Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, Wu SR, Hsiao PW, Huang HP, Shun CT, Lee MS. Androgen-induced TMRPS22 activates mitrapetase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. Cancer Res. 2015;75:2949–60.
5. Zhang J, Chen D, Liang S, Wang J, Liu C, Fan Q, Wang F. mir-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC. Oncol Lett. 2018;15:4619–26.
6. Taunello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano A, Canellas A, Hernando-Mombloña X, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–43.
7. Chen L, Li Y, Wu L, Yu GT, Zhang WF. TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. J Cell Mol Med. 2018;22:1337–49.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
9. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3:83–92.
10. Shyu YA-O, Lee TL, Lu MJ, Chen JR, Chen RN, Chen HY, Lin JF, Tsou AP, Chen YH, Hsieh CW, Huang TS. mir-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J Transl Med. 2016;14(1):200.
11. Lin Y, Chen F, Shen L, Tang X, Du C, Sun Z, Ding H, Chen J. Shen BA-Oho: Biomarker microRNAs for prostate cancer metastasis screened with a network vulnerability analysis model. J Transl Med. 2018;16(1):134.
12. Barrett T, Willhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillips KH, Sherman PM, Holko M, et al. NCBI GEO archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41:D991–5.
13. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–75.
14. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al. mirTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296–302.
15. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
16. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13.
17. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39:D602–8.
18. Chandrashekar DS, Basheel B, Balasubramanayam SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarti B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58.
19. Nagy A, Lanczky A, Menyhart O, Geyoff F. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.
20. Xu F, Zhang J, Hu G, Liu L, Liang W. Hypoxia and TGF-beta1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int. 2017;17:54.
21. Guo Z, Jiang JH, Zhang J, Yang H, Zhong YF, Su J, Yang YR, Li LQ, Xiang BD. Side population in hepatocellular carcinoma HCCLM3 cells is enriched with stem-like cancer cells. Oncol Lett. 2016;11:3145–51.
22. Koumaris C, Valbuena GN, Pomyen Y, Tredwell GD, Nevedomskaya E, Lau CH, Yang T, Benito A, Ellis JK, Keun HC. Systematic integration of molecular profiles identifies mir-22 as a regulator of lipid and folate metabolism in breast cancer cells. Oncogene. 2016;35:7266–76.
23. Zhu B, Gong Y, Yan G, Wang D, Qiao Y, Wang Q, Liu B, Hou J, Li R, Tang C. Down-regulation of IncRNA MEG3 promotes hypoxia-induced human pulmonary artery smooth muscle cell proliferation and migration via repressing PTEN by sponging mir-21. Biochem Biophys Res Commun. 2018;495:2125–32.
24. Liao CG, Kong LM, Zhou P, Yang XL, Huang JG, Zhang HL, Lu N. mir-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC*, uPAR and MMPs. J Transl Med. 2014;12:234.
25. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, et al. TGF-beta-mir-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.
26. Duan HF, Li XQ, Hu HY, Li YC, Cai Z, Mei YS, Xu P, Nie LP, Zhang W, Yu ZD, Nie GH. Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma. Tumour Biol. 2015;36:6679–89.
27. He W, Li Y, Chen X, Lu L, Tang B, Wang Z, Pan Y, Cai S, He Y, Ke Z. miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol. 2014;29:1427–34.
28. Liborio-Kimura TN, Jung HM, Chan EK. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol. 2015;51:151–7.
29. Wang J, Chen H, Liao Y, Chen N, Liu T, Zhang H, Zhang H. Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Tumour Biol. 2015;36:6965–72.
30. Zhi Y, Wu K, Yu D, Wang Y, Yu Y, Yan P, Lu G. MicroRNA-494 inhibits proliferation and metastasis of osteosarcoma through repressing insulin receptor substrate-1. Am J Transl Res. 2016;8:3439–47.
31. Nie ZC, Weng WH, Shang YS, Long Y, Li J, Xu YT, Li Z. MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 2015;8:4745–54.
32. Wang J, Chen X, Su L, Li P, Cai Q, Liu B, Wu W, Zhu Z. MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1. Biomed Pharmacother. 2015;72:66–73.
33. Wang P, Li Z, Liu H, Zhou D, Fu A, Zhang E. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 2016;479:91–6.
34. Yan J, Dang Y, Liu S, Zhang Y, Zhang G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016;37(12):16345–55.